Eikon Therapeutics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Margins
| Current |
|---|
Balance Sheet Health
Current Ratio9.89x
Cash & Equivalents$142.6M
Quality Metrics
Earnings-Beat Rate0.0%
Dividend
No dividend
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Drug discovery leveraging its proprietary technology and clinical development of its product candidates | $0 | View detailsCash, cash equivalents, and marketable securities of $596.0 million as of March 31, 2026, are expected to fund operations into the second half of 2027. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.